Cargando…
Is adjuvant immunotherapy a new standard for non‐pathological complete response patients with resectable esophageal squamous cell carcinoma?
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons Australia, Ltd
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626336/ https://www.ncbi.nlm.nih.gov/pubmed/36214057 http://dx.doi.org/10.1111/1759-7714.14641 |
| _version_ | 1784822708227276800 |
|---|---|
| author | Wang, Jun Hui, Zhouguang Pang, Qingsong |
| author_facet | Wang, Jun Hui, Zhouguang Pang, Qingsong |
| author_sort | Wang, Jun |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9626336 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | John Wiley & Sons Australia, Ltd |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96263362022-11-03 Is adjuvant immunotherapy a new standard for non‐pathological complete response patients with resectable esophageal squamous cell carcinoma? Wang, Jun Hui, Zhouguang Pang, Qingsong Thorac Cancer Letters to the Editor John Wiley & Sons Australia, Ltd 2022-10-10 2022-11 /pmc/articles/PMC9626336/ /pubmed/36214057 http://dx.doi.org/10.1111/1759-7714.14641 Text en © 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Letters to the Editor Wang, Jun Hui, Zhouguang Pang, Qingsong Is adjuvant immunotherapy a new standard for non‐pathological complete response patients with resectable esophageal squamous cell carcinoma? |
| title | Is adjuvant immunotherapy a new standard for non‐pathological complete response patients with resectable esophageal squamous cell carcinoma? |
| title_full | Is adjuvant immunotherapy a new standard for non‐pathological complete response patients with resectable esophageal squamous cell carcinoma? |
| title_fullStr | Is adjuvant immunotherapy a new standard for non‐pathological complete response patients with resectable esophageal squamous cell carcinoma? |
| title_full_unstemmed | Is adjuvant immunotherapy a new standard for non‐pathological complete response patients with resectable esophageal squamous cell carcinoma? |
| title_short | Is adjuvant immunotherapy a new standard for non‐pathological complete response patients with resectable esophageal squamous cell carcinoma? |
| title_sort | is adjuvant immunotherapy a new standard for non‐pathological complete response patients with resectable esophageal squamous cell carcinoma? |
| topic | Letters to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626336/ https://www.ncbi.nlm.nih.gov/pubmed/36214057 http://dx.doi.org/10.1111/1759-7714.14641 |
| work_keys_str_mv | AT wangjun isadjuvantimmunotherapyanewstandardfornonpathologicalcompleteresponsepatientswithresectableesophagealsquamouscellcarcinoma AT huizhouguang isadjuvantimmunotherapyanewstandardfornonpathologicalcompleteresponsepatientswithresectableesophagealsquamouscellcarcinoma AT pangqingsong isadjuvantimmunotherapyanewstandardfornonpathologicalcompleteresponsepatientswithresectableesophagealsquamouscellcarcinoma |